文献速递消化道肿瘤放疗

INTERACT试验:卡培他滨为基础术前放化疗联合同期推量或奥沙利铂强化治疗cT2(远端)-cT3直肠癌的随机试验长期结果

The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer.
PubMed 文献 · Radiother Oncol · 2019-02-07

INTERACT随机试验纳入534例cT2(远端)-cT3直肠癌患者,比较卡培他滨放化疗联合放疗推量(Xelac组)与联合奥沙利铂多药化疗(Xelox组)。Xelac组TRG1-2率显著更高(61.7% vs 52.3%,p=0.039),但两组5年无病生存和总生存无显著差异;Xelox组≥3级血液学和神经毒性更高。

要点

  • Xelac组TRG1-2率61.7%显著高于Xelox组52.3%(p=0.039)。
  • 两组病理完全缓解率24.4% vs 23.8%,无显著差异。
  • Xelox组≥3级血液学毒性和神经毒性显著更高。

核心结论

  • Xelac组显著获得更高的TRG1-2率,但两组临床结局无差异。
  • 基于TRG疗效、毒性更低和依从性良好,Xelac方案或类似放疗剂量强化方案可考虑作为cT3病变的参考治疗。

研究设计与样本

  • 前瞻性、平行组、随机对照试验,2005年6月至2013年9月纳入534例患者,Xelac组280例,Xelox组254例。
  • 纳入低位的cT2N0-2M0、cT3N0-2M0(距肛缘不超过12 cm)病变,排除cT4病变。
  • 主要目标为组间病理结局(TRG 1-2)。

主要发现

  • Xelox组≥3级血液学毒性更高(p=0.01),神经毒性更高(p<0.001)。
  • 98.5%患者接受了治愈性手术。
  • 肿瘤退缩分级分布组间无差异(p=0.102)。
  • TRG 1+2率Xelac组61.7% vs Xelox组52.3%(p=0.039)。
  • 病理完全缓解(ypT0N0)率分别为24.4%和23.8%(p无显著差异)。

关键数值与推荐

  • Xelac方案:盆腔45 Gy/1.8 Gy/日,5次/周,对瘤床加量10 Gy,每次1 Gy,每周两次;同期卡培他滨1650 mg/mq/日。
  • Xelox方案:盆腔45 Gy,对瘤床加量5.4 Gy/1.8 Gy/日,5次/周;同期卡培他滨1300 mg/mq/日,奥沙利铂130 mg/mq,第1、19、38天给药。
  • 手术计划在放化疗后7-9周进行。

临床怎么用

  • 作者认为,基于TRG疗效、毒性更低和依从性良好,Xelac方案或类似放疗剂量强化方案可考虑作为cT3病变的参考治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Capecitabine-based radiochemotherapy (cbRCT) is standard for preoperative long-course radiochemotherapy of locally advanced rectal cancer. This prospective, parallel-group, randomised controlled trial investigated two intensification regimens. cT4 lesions were excluded. PRIMARY OBJECTIVE: pathological outcome (TRG 1-2) among arms. MATERIALS AND METHODS: Low-located cT2N0-2M0, cT3N0-2M0 (up to 12 cm from anal verge) presentations were treated with cbRCT randomly intensified by either radiotherapy boost (Xelac arm) or multidrug concomitant chemotherapy (Xelox arm). Xelac: concomitant boost to bulky site (45 Gy/1.8 Gy/die, 5 sessions/week to the pelvis, +10 Gy at 1 Gy twice/week to the bulky) plus concurrent capecitabine (1650 mg/mq/die). Xelox: 45 Gy to the pelvis + 5.4 Gy/1.8 Gy/die, 5 sessions/week to the bulky site + concurrent capecitabine (1300 mg/mq/die) and oxaliplatin (130 mg/mq on days 1,19,38). Surgery was planned 7-9 weeks after radiochemotherapy. RESULTS: From June 2005 to September 2013, 534 patients were analysed: 280 in Xelac, 254 in Xelox arm. Xelox arm presented higher G ≥ 3 haematologic (p = 0.01) and neurologic toxicity (p < 0.001). Overall, 98.5% patients received curative surgery. The tumour regression grade distribution did not differ between arms (p = 0.102). TRG 1+2 rate significantly differed: Xelac arm 61.7% vs. Xelox 52.3% (p = 0.039). Pathological complete response (ypT0N0) rates were 24.4 and 23.8%, respectively (p non-significant). Median follow-up:5.62 years. Five-year disease-free survival rate were 74.7% (Xelac) and 73.8% (Xelox), respectively (p = 0.444). Five-year overall survival rate were 80.4% (Xelac) and 85.5% (Xelox), respectively (p = 0.155). CONCLUSION: Xelac arm significantly obtained higher TRG1-2 rates. No differences were found about clinical outcome. Because of efficacy on TRG, inferior toxicity and good compliance, Xelac schedules or similar radiotherapy dose intensification schemes could be considered as reference treatments for cT3 lesions.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Valentini V, Gambacorta MA, Cellini F, et al. The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer. Radiother Oncol. 2019. PMID: 31005204. doi:10.1016/j.radonc.2018.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。